The Neuromuscular Disease Network for Canada


Melissa Bowerman

Melissa in the lab(featuredimage)


Lecturer, Bioscience, School of Medicine at Keele University

Group Member of the Wolfson Centre for Inherited Neuromuscular Disease in Oswestry, Principal Investigator in the UK SMA Research Consortium

Email Melissa

Read more about Melissa

Research Interests: Spinal muscular atrophy, drug repurposing, skeletal muscle, metabolism, dietary interventions

Google Scholar profile
ResearchGate profile
ORCiD profile
Twitter profile
Lab website


Dr. Bowerman is a Lecturer in Bioscience at the School of Medicine at Keele University, a group Member of the Wolfson Centre for Inherited Neuromuscular Disease in Oswestry and a principal investigator in the UK SMA Research Consortium.

Dr Bowerman completed her Ph.D. (2006-2012) in Dr Rashmi Kothary’s laboratory (Ottawa Hospital Research Institute (OHRI)/University of Ottawa, Canada) where she held a CIHR Frederick Banting and Charles Best doctoral award and received the OHRI Dr. Ronald G. Worton Researcher in Training Award. Dr. Bowerman then joined Dr. Cedric Raoul’s laboratory at the Institut des Neurosciences de Montpellier in France as an EMBO Long-Term Fellow (2012-2014). From 2014-2016, Dr. Bowerman was a postdoctoral research assistant at the University of Oxford in Professor Matthew Wood’s group. In October 2015, Dr. Bowerman was the recipient of a Junior Research Fellowship at Somerville College, University of Oxford (2015-2017). In January 2016, Dr. Bowerman was awarded and SMA Trust Career Development Fellowship at the University of Oxford.

Dr. Bowerman’s current research interests are on identifying pathological players in skeletal muscle and other metabolic tissues and evaluate how they mediate and exacerbate muscle pathology and metabolic defects in spinal muscular atrophy (SMA). Importantly, a key feature of her work is to develop novel therapeutic approaches (using omics, bioinformatics and drug repurposing strategies) that can be used in combination with clinically relevant SMN gene-based therapies.

For further information on Dr. Bowerman’s research and public engagement activities:

Read Dr. Bowerman’s blog for the NMD4C here:

Recent publications

Betts, CA, Jagannath, A, van Westering, TL, Bowerman, M, Banerjee, S, Meng, J et al.. Dystrophin involvement in peripheral circadian SRF signalling. Life Sci Alliance. 2021.4 (10) PMID:34389686

Meijboom, KE, Volpato, V, Monzón-Sandoval, J, Hoolachan, JM, Hammond, SM, Abendroth, F et al.. Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight. 2021.6 (13) PMID:34236053

Winkelsas, AM, Grunseich, C, Harmison, GG, Chwalenia, K, Rinaldi, C, Hammond, SM et al.. Targeting the 5' untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy. Mol Ther Nucleic Acids. 2021.23 731-742 PMID:33575118

Watson, KS, Boukhloufi, I, Bowerman, M, Parson, SH. The Relationship between Body Composition, Fatty Acid Metabolism and Diet in Spinal Muscular Atrophy. Brain Sci. 2021.11 (2) PMID:33498293

Rademacher, S, Detering, NT, Schüning, T, Lindner, R, Santonicola, P, Wefel, IM et al.. A Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN. Cells. 2020.9 (11) PMID:33153033

Bowerman, M. Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases. Brain Sci. 2020.10 (9) PMID:32932920

Ahlskog, N, Hayler, D, Krueger, A, Kubinski, S, Claus, P, Hammond, SM et al.. Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice. Gene Ther. 2019.27 (10-11)505-515 PMID:32313099

Benlefki, S, Sanchez-Vicente, A, Milla, V, Lucas, O, Soulard, C, Younes, R et al.. Expression of ALS-linked SOD1 Mutation in Motoneurons or Myotubes Induces Differential Effects on Neuromuscular Function In vitro. Neuroscience. 2020.435 33-43 PMID:32234507

Deguise, MO, Baranello, G, Mastella, C, Beauvais, A, Michaud, J, Leone, A et al.. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neurol. 2019.6 (8)1519-1532 PMID:31402618

Šoltić, D, Bowerman, M, Stock, J, Shorrock, HK, Gillingwater, TH, Fuller, HR et al.. Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). Brain Sci. 2018.8 (12) PMID:30518112

See more on PubMed